This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SGN-15

Seattle Genetics, Inc.

Drug Names(s): SGN-15

Description: SGN-15 is an ADC that binds to cancer cells and kills them by delivering the drug doxorubicin inside the cell.

SGN-15 News

Scrip A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

Scrip FDA Hold On Seattle Genetics' Trials Clouds CD33's Suitability for AML

Scrip AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces

Pink Sheet Consumer Health Care Weekly Trademark Review Oct. 25, 2016

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug